- Renovaro’s current product development pipeline includes a variety of treatment candidates spanning cancer, HIV, and HBV
- Renovaro’s Pre-Investigational New Drug (pre-IND) submission included a human study plan covering pancreatic cancer, as well as other cancers that are difficult to treat
- The company recently entered into an LOI with GEDi Cube that could enhance the efficacy of upcoming trials and speed up delivery results
As an advanced, pre-clinical biotechnology company specializing in cell, gene, and immunotherapy, Renovaro BioSciences (NASDAQ: RENB), formerly Enochian BioSciences Inc., aims to unlock potentially long-term or life-long cancer remission in some of the deadliest cancers and to potentially treat or cure serious infectious diseases such as Human Immunodeficiency Virus (“HIV”) and Hepatitis B Virus (“HBV”) infection.
Renovaro’s oncology platform is now at the forefront of the company’s development activities – primarily focused on pancreatic cancer. The company also plans to include other solid tumors with short life expectancy in the first human Phase I/IIa studies that are on track for…
NOTE TO INVESTORS: The latest news and updates relating to RENB are available in the company’s newsroom at https://ibn.fm/RENB
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
